Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
Date:2/17/2011

s who did not receive APC8015F (HR=0.52 [95% CI: 0.37, 0.73]; P=0.0001).  While baseline prognostic factors tended to be more favorable in patients who received APC8015F, treatment with APC8015F remained associated with improved survival after adjusting for these factors (HR=0.55 [95% CI: 0.39, 0.78]; P<0.001).  The safety profile of APC8015F was consistent with that observed in the PROVENGE Phase 3 clinical trials.

Abstract #155: Characterization of Antigen-Specific T cell Activation and Cytokine Expression Induced by Sipuleucel-T

In PROVENGE (sipuleucel-T) Phase 2 and 3 clinical trials, patients underwent leukaphereses to collect peripheral blood mononuclear cells (PBMCs).  For the patients randomized to receive sipuleucel-T, the patient's PBMCs were cultured with PA2024, a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), to generate the treatment (sipuleucel-T), which is then infused into the patient.

This presentation examined the role of GM-CSF in T cell activation and cytokine production in patients in the sipuleucel-T Phase 2 and 3 clinical trials (P07-2 ProACT and D9902B IMPACT).  For this analysis, a portion of PBMCs from each leukapheresis were cultured with GM-CSF and compared to sipuleucel-T (PBMCs cultured with PA2024) to evaluate T cell activation, cytokine production, and upregulation of the costimulatory molecules, CD54 and CD86.

The study showed a statistically significant increase in the production of a number of cytokines, including IL-2 (P<0.0001) and IFNγ (P=0.0019), from cells cultured with PA2024 compared to those cultured with GM-CSF.  Furthermore, CD54 upregulation was enhanced at week 2 in response to PA2024 but not GM-CSF.  The increased T cell activation and enhanced cytokine expression which occurred after the first infusion of sipuleucel-T also appeared to be PA2024-specific
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... Oncothyreon Inc. (NASDAQ: ONTY ) today announced ... offerings of 10,000,000 shares of its Common Stock at ... for expected gross proceeds of $20 million and 10,000 ... a price to the public of $2,000.00 per share, ... of Series A Convertible Preferred Stock is non-voting and ...
(Date:9/18/2014)... 2014   Sigma-Aldrich Corporation (Nasdaq: ... into a new gene editing partnership with the ... Under the partnership, Sigma-Aldrich will provide the Vector ... and dedicated gene editing bioinformaticians. The ... at the U-M Medical School. One initiative already ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... Mich., Sept. 26 MichBio, the,association for Michigan,s life ... held October 16 in East Lansing. Michigan State,University has ... event on,its campus. Career Day is intended to introduce ... educational and career opportunities in,the life sciences. It takes ...
... HILL, N.C., Sept. 26 The landscape of ... the advent of,transparency guidelines. Half of global publications ... publications leaders foresee a shift,to medical groups to ... by Best Practices, LLC. In a benchmarking ...
... Mylan Laboratories Inc.,(NYSE: MYL ) will host ... acquisition. Pending the closing, the investor day will take ... Robert J. Coury, Mylan,s,Vice Chairman and Chief Executive Officer, ... Generics and Matrix Laboratories will,provide a detailed financial and ...
Cached Biology Technology:MichBio Announces Student Career Day at Michigan State University 2Industry Executives Finding Value in Shift of Scientific Publications 2
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
(Date:9/17/2014)... instrumental in the creation of the Santa Ana Wildfire ... fire threat potential of the powerful, hot, dry Santa ... inferno. The index was introduced Sept. 17 by the ... Diego Gas and Electric. , The index includes four ... be used to help fire agencies and other emergency ...
(Date:9/17/2014)... SAN DIEGO, Calif. (Sept. 17, 2014) A rare genetic ... autism, according to a recent joint investigation by researchers ... California, San Diego. In addition to suggesting better treatment ... offers more clues into the genetic underpinnings of autism., ... to the National Institutes of Health. It occurs in ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2
... and Environmental Engineering suggests how aquatic plants in rivers and ... large areas of ocean coastal waters. This work, ... of Fluid Mechanics (JFM), describes the physics of water flow ... to environmental engineering. This new understanding can be used to ...
... and Budget evaluates R&D programs at the U.S. Environmental ... asks about many aspects of their research, including its ... and an "ineffective" rating can have serious adverse consequences ... meeting OMB,s requirements to measure and demonstrate efficiency, EPA ...
... US national grids has enabled UCL (University College London) scientists ... a key protein used by the lethal virus. The method ... action could one day be used to tailor personal ... their drugs. The study, published online today in the ...
Cached Biology News:River plants may play major role in health of ocean coastal waters 2Virtual human in HIV drug simulation 2
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
... ARG. Vasopressin The antibody blocks ... are found in the paraventricular and ... throughout the hypothalmus in rat brain ... Immunogen: Arginine Vasopression ...
Pronase Reagent...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Biology Products: